Feature

Highly anticipated HIV vaccine fails in large trial


 

The only HIV vaccine nearing the completion of testing trials is not effective at preventing HIV, officials announced Wednesday.

The vaccine had been in development since 2019 and was given to 3,900 study participants through October 2022, but data shows it does not protect against HIV compared with a placebo, according to developer Janssen Pharmaceutical.

Experts estimate the failure means there won’t be another potential vaccine on the horizon for 3 to 5 years, the New York Times reported.

“It’s obviously disappointing,” Anthony Fauci, MD, former head of the National Institute of Allergy and Infectious Diseases, told MSNBC, noting that other areas of HIV treatment research are promising. “I don’t think that people should give up on the field of the HIV vaccine.”

No safety issues had been identified with the vaccine during the trial, which studied the experimental treatment in men who have sex with men or with transgender people.

There is no cure for HIV, but disease progression can be managed with existing treatments. HIV attacks the body’s immune system and destroys white blood cells, increasing the risk of other infections. More than 1.5 million people worldwide were infected with HIV in 2021 and 38.4 million people are living with the virus, according to UNAIDS.

A version of this article first appeared on WebMD.com.

Recommended Reading

AAP approves CDC’s child/adolescent vax schedule for 2022
Journal of Clinical Outcomes Management
Full results of anal cancer study point to barriers to care
Journal of Clinical Outcomes Management
Honoring Dr. Paul Farmer: Dr. Serena Koenig shares her memories of working with him
Journal of Clinical Outcomes Management
FDA approves HIV injectable Cabenuva initiation without oral lead-in
Journal of Clinical Outcomes Management
HIV care continuum conundrum: Challenges of out-of-care patients
Journal of Clinical Outcomes Management
Aging HIV patients face comorbidities and hospitalizations
Journal of Clinical Outcomes Management
Fourth patient cleared of HIV after stem cell transplant for blood cancer
Journal of Clinical Outcomes Management
Prolonged remission in patient with HIV may open new avenues to functional cure
Journal of Clinical Outcomes Management
Opt-out HIV testing in EDs can help identify undiagnosed cases
Journal of Clinical Outcomes Management
FDA approves first-in-class drug for HIV
Journal of Clinical Outcomes Management